Orexigen Therapeutics Inc. (OREX) Stock Price Up 7.3%
Orexigen Therapeutics Inc. (NASDAQ:OREX) shares rose 7.3% on Thursday . The stock traded as high as $3.57 and last traded at $3.53, with a volume of 173,421 shares. The stock had previously closed at $3.29.
Separately, Zacks Investment Research raised Orexigen Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, April 7th. One investment analyst has rated the stock with a sell rating and eight have given a hold rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $2.61.
The company’s 50-day moving average is $4.04 and its 200-day moving average is $7.25. The company’s market cap is $51.09 million.
Orexigen Therapeutics (NASDAQ:OREX) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.73) earnings per share for the quarter, missing the consensus estimate of ($1.47) by $0.26. The business had revenue of $7.79 million for the quarter, compared to analysts’ expectations of $6.88 million. The business’s quarterly revenue was up 50.0% on a year-over-year basis. During the same quarter last year, the firm posted ($0.18) EPS. On average, equities research analysts anticipate that Orexigen Therapeutics Inc. will post ($5.61) EPS for the current fiscal year.
Orexigen Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company’s product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.